Zhejiang Medicine Co., Ltd. (SHA:600216)
China
· Delayed Price · Currency is CNY 13.76
+0.25 (1.85%)
May 23, 2025, 2:45 PM CST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2016 - 2018 |
| Vitamin E | 2.79B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vitamin E Growth | -19.27% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Social Delivery Series | 2.24B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Social Delivery Series Growth | 5.03% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vitamin A | 495.21M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vitamin A Growth | -3.71% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Levofloxacin Series | 442.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Levofloxacin Series Growth | 13.46% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vancomycin Hydrochloride | 398.87M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vancomycin Hydrochloride Growth | 4.64% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Nerofloxacin Malate Series | 325.03M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Nerofloxacin Malate Series Growth | 87.06% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Miglitol Series | 221.82M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Miglitol Series Growth | -5.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Teicoplanin Series | 182.56M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Teicoplanin Series Growth | 1.82% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Progesterone Series | 76.53M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Progesterone Series Growth | -22.72% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 622.98M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 20.74% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Carotenoid | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Carotenoid Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Kolanin | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Kolanin Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Natural Vitamin E series | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Natural Vitamin E series Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Datomosan Raw Material | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2016 - 2018 |
| China | 5.63B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Growth | 5.35% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Overseas | 3.07B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Overseas Growth | -21.55% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Inter-segment Offset | -907.77M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Inter-segment Offset Growth | -23.49% |
Log In |
Log In |
Log In |
Log In | Upgrade
|